Wolverine+: BPC-157 / TB-500 / MGF (10mg / 2.5mg / 1mg)

BPC-157 and TB-500 — See Wolverine Peptide I

The mechanisms of BPC-157 (VEGFR2/Akt-eNOS angiogenesis, FAK-paxillin fibroblast activation, mesenchymal stem cell recruitment, nitric oxide modulation, GI cytoprotection) and TB-500 (G-actin sequestration, cellular migration, endothelial mobilization, ILK-Akt cell survival, anti-fibrotic remodeling) are comprehensively detailed in the Wolverine Peptide I product page and the GHK-Cu/TB-500/BPC-157 blend page. They are unchanged in this combination and operate with the same pharmacological independence and complementarity.

MGF — Satellite Cell Activation and the Myogenic Stem Cell Axis

MGF’s mechanism is the most precisely targeted of the three compounds — a single, well-defined biological signal that initiates the stem cell program responsible for muscle fiber regeneration and adaptation:

The MGF Hypothesis — Muscle Repair at the Genetic Level

Endogenous MGF arises from alternative splicing of the IGF-1 pre-mRNA in non-hepatic mechanically loaded tissues:

• The standard liver-type IGF-1 (IGF-1Ea) uses exon 6 for its E-domain
• MGF uses a frame-shifting insert (52 base pairs in humans, 49 in rodents) that changes the reading frame of exon 5 entirely, producing a novel C-terminal E-peptide sequence with no homology to the liver IGF-1 Ea-domain
• This novel E-domain — the synthetic fragment sold as MGF — is the bioactive unit that activates satellite cells, while the mature IGF-1 domain of the same propeptide drives differentiation later

Satellite Cell Activation — The Core Function

The most well-characterized role of MGF is activation of quiescent muscle satellite cells (also called myogenic stem cells):

• Satellite cells normally reside in a quiescent state beneath the basal lamina of muscle fibers, held there by Notch signaling and low-level inhibitory signals
• Muscle mechanical damage disrupts these inhibitory signals and triggers the immediate MGF expression pulse — MGF is then the first molecular signal these satellite cells receive instructing them to exit quiescence and enter the cell cycle
• MGF binding drives satellite cells into G1-S phase transition — they begin proliferating to expand the myogenic precursor pool that will ultimately supply new nuclei to repair damaged fibers and support hypertrophy​
• Critically, the MGF E-peptide achieves this without binding the IGF-1 receptor — it activates satellite cells through a distinct cell surface receptor and likely via nuclear signaling, explaining why MGF and IGF-1 have additive rather than redundant effects in muscle

Receptor-Independent Mechanism — Why MGF Is Not Just IGF-1

The distinction between MGF and systemic IGF-1 is mechanistically crucial and frequently misunderstood:

• IGF-1 binds IGF-1R → PI3K-Akt-mTOR and Ras-MAPK → protein synthesis, differentiation, anti-apoptosis
• MGF E-peptide activates satellite cells through a pathway that anti-IGF-1R antibodies (which block IGF-1 signaling) do not inhibit — confirming truly independent receptor biology​
• MGF also delays differentiation of myoblasts while proliferation is occurring — preventing the premature commitment to mature fibers that would prematurely terminate the stem cell expansion phase​
• Once MGF levels fall (which happens naturally due to rapid degradation, or intentionally with short-acting unmodified MGF), the IGF-1Ea splice variant and systemic IGF-1 take over — driving the differentiation and fusion of the expanded satellite cell pool​

Mesenchymal Stem Cell Chemotaxis

Beyond muscle satellite cells, the MGF E-domain peptide directly stimulates human mesenchymal stem cell (hMSC) migration — in culture studies, MGF E-peptide produced MSC migration responses greater than IGF-1 itself:​

• This MSC chemotaxis provides additional repair cell supply to the injury site, complementing BPC-157’s own MSC recruitment mechanism with a parallel, growth factor-mediated signal​

Cardiac Protection and Apoptosis Inhibition

MGF demonstrates important anti-apoptotic effects in hypoxic and ischemic cell populations:​

• In cardiomyocyte models subjected to hypoxia, MGF inhibited programmed cell death and promoted cardiac stem cell recruitment to the infarct zone
• In skeletal muscle, MGF suppresses expression of inflammatory cytokines and oxidative stress markers following injury — reducing the secondary damage phase that follows the initial mechanical injury
• The PI3K/Akt survival pathway is engaged by MGF in cardiomyocytes, protecting cells in the ischemic environment before vascular repair (mediated by BPC-157 and TB-500 angiogenesis) can restore oxygen delivery

Bone, Cartilage, and Neurogenic Dimensions

MGF’s tissue effects extend well beyond skeletal muscle:

• Bone: MGF E-peptide accelerated bone defect healing and osteoblast proliferation in rabbit models — establishing ossification at injury sites more rapidly than controls​
• Cartilage: MGF is expressed in growth plate cartilage; MGF peptide promotes chondrocyte migration via the p38 MAPK pathway, attenuating mechanical overload-induced chondrocyte apoptosis relevant to joint injuries
• Neurogenesis: MGF overexpression increased proliferating cells in the dentate gyrus and subventricular zone of the mouse hippocampus, with preserved olfactory function at 24 months — suggesting a neurogenic dimension relevant to TBI recovery​
• ALS/Motor neuron protection: MGF plasmid injections in SOD1(G93A) ALS mice rescued motoneurons and improved muscle function — a neuroprotective effect mediated through the same satellite cell and anti-apoptotic pathways active in peripheral muscle​

MGF vs. PEG-MGF — The Critical Formulation Decision

This blend uses unmodified MGF rather than PEG-MGF — a deliberate pharmacological choice:

The biological rationale for preferring unmodified MGF at 1mg: MGF’s endogenous role is a pulse — not sustained elevation. Providing a brief, acute satellite cell activation signal at the injury site more accurately replicates what the body does naturally following mechanical damage, and avoids the differentiation-suppressing effect that prolonged MGF exposure can produce.

The Three-Tier Division of Labor

BPC-157 and TB-500 Evidence

Comprehensively covered in the BPC-157 product page and Wolverine Peptide I product page. BPC-157 has the richest musculoskeletal preclinical evidence of any peptide in this catalog (35 preclinical studies in the 2025 AJSM systematic review); TB-500 has Phase 1 IV safety data and Phase 2 cardiac and wound-healing trial data.

MGF Research Evidence

Human Expression Studies

• Hameed et al. (2003), Journal of Physiology: First demonstration of MGF expression in human skeletal muscle following exercise — eccentric quadriceps exercise in young men produced a rapid rise in IGF-IEb (MGF) mRNA within the first 24–48 hours, followed by a delayed rise in IGF-IEa, confirming the sequential splice variant expression pattern in humans​
• Hameed et al. (2008), Journal of Physiology: Following acute damaging lengthening contractions in 8 healthy subjects, MGF mRNA was upregulated at 24 and 72 hours post-exercise, temporally correlated with MyoD expression (satellite cell activation marker) — providing human in vivo evidence for the MGF-satellite cell link​

In Vitro and Animal Studies

• Sigma et al. (2004), PNAS: Transgenic mice expressing local IGF-1 (muscle-type, analogous to MGF isoform) showed markedly enhanced muscle regeneration, with increased bone marrow stem cell recruitment to injured muscle — demonstrating stem cell mobilization function​
• Hede et al. (2011), Mech. Ageing Dev.: MGF E-peptide activated human muscle progenitor cells from both young and elderly donors, increasing myogenic precursor numbers and fusion potential — with the effect preserved in aged cells, suggesting utility in age-related muscle loss​
• Dluzniewska et al. (2005), Experimental Neurology: MGF E-peptide rescued motoneurons and improved muscle function in SOD1(G93A) ALS mice via IGF-1R-independent mechanism — key evidence that MGF’s biological activity is structurally distinct from systemic IGF-1​
• Neurogenesis (Pons-Espinal et al., 2017): Conditional overexpression of MGF in mice increased BrdU+ proliferating and differentiating cells in olfactory bulbs and dentate gyrus at 24 months — demonstrating cross-tissue stem cell activation beyond skeletal muscle​
• Cartilage (2023 review): MGF gene and mRNA upregulation confirmed following cartilage injury in multiple studies; MGF promoted chondrocyte migration and survival under mechanical overload and hypoxic stress via p38 MAPK​
• Bone: PEG-MGF promoted osteoblast proliferation and bone defect healing in rabbit models, with MGF E-peptide producing comparable effects in chondrocyte and osteoblast cultures​

The “Fall of Mechano Growth Factor” Controversy

A 2013 editorial in Endocrinology raised important challenges to the MGF hypothesis:​

• Questioned whether endogenous E-peptide is actually processed and secreted in free form in vivo, or whether it remains part of the pro-IGF-1 propeptide
• Cited conflicting in vitro data showing that some MGF satellite cell effects could be replicated by IGF-1 under appropriate conditions — raising questions about receptor-independence claims
• Concluded that while MGF mRNA expression data in humans is robust, the specific bioactivity of the synthetic E-peptide as a discrete signaling molecule independent of IGF-1R remains not definitively established and should be considered “speculative but plausible”

This controversy is important to acknowledge honestly in any product communication — MGF’s evidence base is real but not yet as clean as its proponents sometimes suggest. The 2010 minireview in Endocrinology by Goldspink (the original cloner of MGF) provides a balanced synthesis.

No human clinical trial data exists for exogenous synthetic MGF administration by any route in any indication.​

WADA Status — Most Prohibited Blend in This Catalog

All three compounds in this blend are on the WADA 2026 Prohibited List under Section S2.2.5 (Growth Factors) or S0:

• BPC-157: Section S0 — Non-Approved Substances — banned at all times
• TB-500 (Thymosin β4 fragments): Section S2.2.5 — “Thymosin-β4 and its derivatives e.g. TB-500” — banned at all times
• MGF: Section S2.2.5 — “Mechano growth factors (MGFs)” — explicitly listed by class name — banned at all times

USADA explicitly notes: “All forms of exogenous IGF-1 are prohibited at all times, and any substance containing any form of exogenous IGF-1 should be considered prohibited” — MGF is an IGF-1 splice variant and falls squarely within this prohibition. The DoD Prohibited Dietary Supplement Ingredients list similarly prohibits IGF-1 and growth factors including MGFs, making this blend prohibited for U.S. military personnel as well.

FDA Status

• PEG-MGF (the pharmacokinetically modified form): Explicitly on FDA Section 503A and 503B Category 2 lists; FDA issued 23 warning letters to peptide suppliers between 2022–2025 with 8 specifically citing PEG-MGF violations; a 2023 federal case (USA v. Enhanced Athletic Performance LLC) resulted in $2.3 million in civil penalties and permanent injunction
• Unmodified MGF: Same regulatory concern applies — the FDA’s stated rationale (immunogenicity risk for IGF-1 variants, lack of dosing parameters, potential for uncontrolled cell proliferation via PI3K/Akt) applies to both modified and unmodified forms
• BPC-157 and TB-500: Both on Category 2, subject to ongoing PCAC review following the 2024 Evexias/Farmakeio legal settlement​

2026 RFK Jr. Announcement: HHS Secretary announced that approximately 14 of 19 restricted peptides would return to legal compounding status — the specific peptides and timeline of this potential reclassification remain to be formally implemented as of early 2026​

BPC-157 and TB-500 Safety

Detailed in the BPC-157 product page and Wolverine Peptide I product page. Summary: BPC-157 has an excellent preclinical safety profile with no identified lethal dose, organ toxicity, mutagenicity, or teratogenicity; TB-500 has Phase 1 IV safety data with no serious adverse events. Both carry immunogenicity concerns from research chemical manufacturing quality.

MGF Safety

• No published human safety data exists for synthetic MGF administered by any route​
• Preclinical safety: In animal models, MGF injection produced no documented acute organ toxicity or serious adverse effects; its transient expression profile (degraded within minutes) limits exposure duration​
• PEG-MGF immunogenicity: Animal studies document 15–25% anti-PEG antibody formation with PEG-MGF — a significant safety concern that drove FDA’s Category 2 placement; unmodified MGF avoids PEG-related immunogenicity​
• IGF-1 pathway cancer concern: MGF activates PI3K/Akt signaling in cardiomyocytes and satellite cells — the same pathway that mediates IGF-1’s cancer-promoting effects in susceptible populations. The cell proliferation activity (satellite cell expansion) that makes MGF therapeutically interesting also theoretically creates cancer risk in individuals with pre-existing malignancies or at high cancer risk; this is the FDA’s explicit stated concern for all IGF-1 variant peptides
• No anti-doping detection method: No published WADA accredited laboratory method exists for detecting synthetic MGF in blood or urine; anti-doping testing for this compound is not yet operational​
• Manufacturing quality: MGF is a short peptide with a simple sequence that is relatively straightforward to synthesize; purity and sequence verification remain critical given the absence of regulatory oversight

Combination Safety Considerations

• No pharmacological antagonism between the three compounds is expected — they operate through distinct pathways with no known adverse interactions​
• The convergence of three independent pro-angiogenic mechanisms (BPC-157 VEGFR2, TB-500 endothelial migration, MGF cardiac stem cell/endothelial recruitment) is additive rather than synergistic from a safety perspective — no supra-physiological angiogenic risk has been characterized, but the theoretical concern applies in oncology settings
• Common adverse effects: Injection site reactions (all three); transient flushing/vasodilation (BPC-157); local tissue discomfort (MGF)
• The lowest MGF dose (1mg) in this formulation reflects appropriate conservatism given the absence of human dose-response data

MGF

1. Goldspink, G. (2003). Expression of insulin-like growth factor-I splice variants and satellite cell activation following muscle damage in humans. Journal of Physiology, 549(Pt 1), 147–164. 
2. Goldspink, G. (2010). Minireview: Mechano-Growth Factor: A Putative Product of IGF-I Gene Expression Involved in Tissue Repair and Regeneration. Endocrinology, 151(3), 865–875. 
3. Goldspink, G. (2020). MGF: a local growth factor or a local tissue repair factor? Physiology News Magazine, 53, 22. 
4. Hede, M.S., et al. (2011). MGF-E peptide activates human muscle progenitor cells at different ages. Mechanisms of Ageing and Development, 132(4), 154–162. 
5. Dluzniewska, J., et al. (2005). Mechano-growth factor, an IGF-I splice variant, rescues motoneurons in SOD1(G93A) mice. Experimental Neurology, 198(2), 427–438. 
6. Hameed, M., et al. (2008). Co-expression of IGF-1 family members with myogenic regulatory factors following acute damaging muscle-lengthening contractions in humans. Journal of Physiology, 587(1), 253–261. 
7. Pons-Espinal, M., et al. (2017). Mechano growth factor promotes neurogenesis in the aging mouse brain. Molecular Brain, 10, 47. 
8. Liu, X., et al. (2021). Migration and proliferation of human mesenchymal stem cells is stimulated by MGF E-domain. Growth Factors, 29(4), 157–166. 
9. Tan, Z., et al. (2023). The role of mechano growth factor in chondrocytes and cartilage repair. Frontiers in Physiology, 14, 1124699. 
10. Brisson, B.K., et al. (2014). Controversy on the fall of mechano growth factor. Endocrinology, 155(1). 
11. Core Peptides. (2024). PEG-MGF Peptide Research in Tissue Repair and Cell Regeneration. 
12. BioTech Peptides. (2021). MGF vs PEG-MGF Research in Muscle Regeneration. 

BPC-157 and TB-500 — see Wolverine Peptide I and BPC-157 dedicated pages.

Regulatory
13. World Anti-Doping Agency. 2026 Prohibited List, Section S2.2.5. 
14. USADA. IGF-1 and the WADA Prohibited List. 
15. MyPeptideMatch. (2026). PEG-MGF Legal Status: FDA Regulations and Patient Guidance. 
16. U.S. FDA. Substances in Compounding that May Present Significant Safety Risks. 
17. Elite NP. (2026). FDA Peptide Reclassification 2026.